Cardiology Today Current Issue

The following articles appeared in the print edition of Cardiology Today.

Table of Contents

• As controversy wanes, efforts shift to implementation of ACC/AHA guidelines Erik Swain
• Cardiologist shortage on the horizon L. Samuel Wann, MD, MACC, FESC
• FDA approves drug-coated angioplasty balloon catheter for PAD treatment
• FDA advisory panel split on revote for LAA closure device
• CHARISMA: Beta-blockers lowered CV events in patients with MI
• Elderly patients more likely to adhere to generic statins than brand-name statins
• Ezetimibe initiations declined, discontinuations increased after announcement of ENHANCE trial data
• Greater physical activity linked to lower rates of AF in postmenopausal women
• Long-term survival, stroke rates similar between bioprosthetic, mechanical aortic valve replacement
• Low-risk behaviors could prevent four of five MIs in men
• Oral contraceptive use had no beneficial, harmful effect in patients with long QT syndrome
• Responses to mental stress differ between men, women with ischemic heart disease
• Routine ECG screening discouraged for young people
• Scientific statement encourages discussion of radiation risks before CV imaging
• Strict glycemic control did not affect survival after CABG
• TeleStroke units improved stroke care at rural hospitals
• Andexanet alfa achieved primary, secondary efficacy endpoints in phase 3 trial
• Mount Sinai receives $1.1 million to assess heart, kidney disease in 9/11 responders
• Larry B. Goldstein, MD, FAAN, FANA, FAHA: A tireless advocate for stroke prevention
• ACC changes recommendations on complete revascularization
• AMIO-CAT: Amiodarone improved short-term recovery after AF ablation
• Beta-blockers failed to reduce mortality in patients with HF, AF
• Biventricular pacing cost-effective for patients with atrioventricular block, left ventricular dysfunction
• BRIGHT: Bivalirudin outperformed heparin alone, heparin plus tirofiban in PCI
• CLP-1001 failed to improve symptoms, exercise performance in patients with HF
• CoreValve cost effective for high-risk patients undergoing TAVR
• ENGAGE AF-TIMI 48: Edoxaban dose reduction improved clinical outcomes
• FOCUS: Polypill improved adherence to treatment after MI
• ISAR TRIPLE: Shorter duration of triple therapy not superior to longer duration
• MITOCARE: Investigational agent failed to prevent reperfusion injury in STEMI
• MORE-CRT: Quadripolar leads reduced risk for complications
• NOMI: Nitric oxide did not reduce infarct size in STEMI
• Once-daily ZS-9 improved, maintained serum potassium levels in patients with HF, hyperkalemia
• PARACHUTE III: Percutaneous ventricular restoration device safe in patients with ischemic dilated HF
• PARTNER I: TAVR delivers mortality benefit, decreases rehospitalization at 5 years
• Patiromer safe, effective for hyperkalemia, regardless of HF status
• Renal denervation failed to reduce MACE at 1 year
• SECURITY: 6-month DAPT performed similar to 12 months with DES implantation
• SIGNIFY: Ivabradine did not improve outcomes in stable CAD
• Symplicity Flex: Renal denervation misses primary endpoint in patients with mild hypertension
• The role of new PAH therapies Melissa R. Meyer, PharmD; Karen J. McConnell, PharmD, FCCP, BCPS (AQ Cardiology); Sarah A. Spinler, PharmD, FCCP, FAHA, FASHP, AACC, BCPS (AQ Cardiology)
• Trial Scorecard: AMIO-CAT
• Trial Scorecard: BLOCK-HF
• Trial Scorecard: BRIGHT
• Trial Scorecard: CHARISMA
• Trial Scorecard: CLEAN-TAVI
• Trial Scorecard: COPPS-2
• Trial Scorecard: EXCITE ISR
• Trial Scorecard: PARACHUTE III